SYBR Green实时定量PCR检测乳腺癌组织CXCR4基因的表达  

Expression analysis of CXCR4 in primary breast carcinoma tissues by SYBR Green quantitative real-time PCR

作　　者：姜政[1] 周伟[2] 宋丽华[3] 刘燕冰 徐风华[2] 王兴武[5] 

机构地区：[1]山东大学齐鲁医院神经外科,山东济南250012 [2]山东省肿瘤防治研究院放疗科,山东济南250117 [3]山东省肿瘤防治研究院化疗科,山东济南250117 [4]山东省肿瘤防治研究院乳腺中心,山东济南250117 [5]山东省肿瘤防治研究院基础研究中心,山东济南250117

出　　处：《中华肿瘤防治杂志》2009年第15期1155-1158,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：山东省自然科学基金资助项目(Q2006C16);山东省优秀中青年科学家科研奖励基金(博士基金)项目(2008BS02025)

摘　　要：目的:运用实时定量PCR检测趋化因子受体CXCR4基因在人乳腺癌组织中的表达及其与肿瘤恶性程度之间的关系。方法:SYBR Green实时定量PCR方法定量检测CXCR4 mRNA在63例乳腺癌(TNM分期:Ⅰ期9例,ⅡA期25例,ⅡB期13例,ⅢA期16例)和20例正常乳腺组织中的表达;采用Kruskal-Wallis检验、Mann-Whit-ney检验等分析CXCR4 mRNA表达在不同临床参数间的表达差异。结果:乳腺癌组织CXCR4 mRNA表达水平(1.22±0.80)高于正常乳腺组织(0.65±0.59),P=0.001。CXCR4 mRNA在乳腺癌中表达上调与淋巴结转移数目(>3个)、HER-2表达情况(+++)密切相关,P值分别为0.013和0.031。但CXCR4 mRNA在不同年龄、绝经情况、组织学分级、病理类型、肿瘤大小以及其他免疫组化指标(ER、PR、p53和Ki-67)组间的差异均无统计学意义,P>0.05。结论:趋化因子受体CXCR4表达可作为预测乳腺癌转移的生物学指标,有望成为乳腺癌治疗的新靶点。OBJECTIVE： To detect the expression of CXCR4 mRNA in human primary breast carcinoma tissues by quantitative real time PCR, and analysis its correlation with tumor progression. METHODS： The expression of CXCR4 mRNA was detected by SYBR Green quantitative real-time PCR in 63 primary breast carcinoma samples and 20 normal breast tissues from patients （9 of stage Ⅰ , 25 of stage ⅡA, 13 of stage liB, and 16 of stage ⅢA）. The CXCR4 mRNA expression levels in various clinical characteristics were evaluated using the Kruskal-Wallis test and the Mann-Whitney test. RESULTS.. Quantitative analysis of the CXCR4 transcript revealed significantly （P=0. 001） higher levels in breast carcinoma tissues （1.22±0.80） than that in normal mammary tis sues （0.65±0.59）. CXCR4 overexpression in primary breast carcinomas was significantly related to lymph node metastasis （〉3 positive lymph nodes metastasis, P--0. 013）, and strong HER-2 expression （＋＋＋, P=0. 031）. However, no links （P〉0. 05） were found between CXCR4 mRNA expression levels and age, menopausal status, histological grade, tumor type, macroscopic tumor size, or other standard immunohistochemical parameters （ER, PR, p53, and Ki-67）. CONCLUSIONS： CXCR4 can be a marker to predict tumor metastasis. It is a potential therapeutic target in patients with breast carcinoma.

关 键 词：乳腺肿瘤 受体 CXCR4 聚合酶链反应 SYBR Green 

分 类 号：R737.9[医药卫生—肿瘤]